Pharmaceutical company Amneal Pharmaceuticals (NASDAQ: AMRX) will be reporting results this Friday morning. Here’s what you need to know.
Amneal beat analysts’ revenue expectations last quarter, reporting revenues of $784.5 million, up 11.7% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and full-year revenue guidance slightly topping analysts’ expectations.
Is Amneal a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Amneal’s revenue to grow 10.5% year on year, slowing from the 18.4% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amneal has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Amneal’s peers in the pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 42.6%, beating analysts’ expectations by 7.4%, and Bristol-Myers Squibb reported revenues up 1.4%, topping estimates by 4.8%. Eli Lilly traded up 1.7% following the results while Bristol-Myers Squibb was also up 7.6%.
Read our full analysis of Eli Lilly’s results here and Bristol-Myers Squibb’s results here.
Investors in the pharmaceuticals segment have had fairly steady hands going into earnings, with share prices down 1.1% on average over the last month. Amneal is up 7.5% during the same time and is heading into earnings with an average analyst price target of $15.20 (compared to the current share price of $14.58).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
